Assessment of Eravacycline Antimicrobial Susceptibility in China During the First Year Following Regulatory Approval (2023-2024): A Real-World Study. [PDF]
MicroorganismsYi Q, Li Y, Zhou M, Jing R, Lu M, Xu Y.
europepmc +1 more source
New Insights into <i>Acinetobacter baumannii</i> Pathogenesis and Therapeutic Implications. [PDF]
PathogensMorena R +5 more
europepmc +1 more source
Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study. [PDF]
Front Cell Infect MicrobiolZhang J +5 more
europepmc +1 more source
Marine Antimicrobial Peptide as a Promising Alternative to Polymyxin B. [PDF]
Mar DrugsSafronova VN +16 more
europepmc +1 more source
Antibiotic Consumption and Gram-Negative Resistance Dynamics in the ICU: A Five-Year Autoregressive Integrated Moving Average (ARIMA) Analysis. [PDF]
CureusRakovac Tupkovic L +7 more
europepmc +1 more source
Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases. [PDF]
Braz J Infect DisZavascki AP +6 more
europepmc +1 more source
Anti-Infective-Associated AKI: A Narrative Review of the Epidemiology, Mechanisms, Risk Factors, Biomarkers, Clinical Course, Monitoring, Prevention, and Therapeutic Strategies. [PDF]
Antibiotics (Basel)Karimzadeh I, Kane-Gill SL, Ma B.
europepmc +1 more source
Lipopolysaccharide-targeting treatments for multidrug-resistant <i>Pseudomonas aeruginosa</i>. [PDF]
Expert Opin Ther TargetsWang M, Kirienko NV.
europepmc +1 more source
Structural determinants of ligand response specificity in the mast cell activating GPCR, MRGPRX2. [PDF]
J Biol ChemAdeosun AAR +3 more
europepmc +1 more source